pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·8h ago·1 min read
save

Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event

Nov 17, 2026·read at Fierce Biotech ↗

Panelists at Fierce Biotech's London Life Sciences Week event discussed whether Europe can pull its weight in biopharma investment next year against the gravitational pull of the U.S. and China.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 6h agoIsomorphic Labs raises $5B series C months after $2.1B roundFierce Biotech
  • 12h agoLilly signs $5.9B deal with Stipple to unlock oncology targetsFierce Biotech
  • 17h agoAriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing optionFierce Biotech
  • 21h agoSellas marks 9-month survival benefit in late-stage leukemia vaccine studyFierce Biotech
  • 1d agoCG preps new, expanded bladder cancer plans with FDA after ph. 3 winFierce Biotech